[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335438-105":59,"doc-detail-335438-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteomic-profiling-reveals-ceacam6-function-in-driving-gallbladder-cancer-aggressiveness-through-integrin-receptor-prkcd-and-akterk-signaling-positive-cancers","Proteomic Profiling Reveals CEACAM6 Function in Driving Gallbladder Cancer Aggressiveness through Integrin Receptor - PRKCD and AKT/ERK Signaling - positive cancers","","Proteomic profiling identifies CEACAM6 as a markedly upregulated protein in gallbladder cancer (GBC), linking it to poor clinical outcomes and limited treatment options. Combining quantitative proteomics of FFPE GBC samples with in vitro assays and mouse models, the study shows CEACAM6 promotes early progression and metastasis by reducing cell adhesion while enhancing migration and invasion. CEACAM6 knockdown reverses aggressiveness by increasing adhesion and suppressing migration, proliferation, and colony formation. Mechanistically, ITGB1 and PRKCD are direct partners that regulate ERK/AKT signaling; AKT inhibitor capivasertib or ERK inhibitor ulixertinib mitigates CEACAM6-driven migration, supporting CEACAM6-targeted therapeutic strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteomic-profiling-reveals-ceacam6-function-in-driving-gallbladder-cancer-aggressiveness-through-integrin-receptor-prkcd-and-akterk-signaling-positive-cancers/335438/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteomic-profiling-reveals-ceacam6-function-in-driving-gallbladder-cancer-aggressiveness-through-integrin-receptor-prkcd-and-akterk-signaling-positive-cancers/335438.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does CEACAM6 play in gallbladder cancer aggressiveness?","Question",{"text":112,"@type":113},"CEACAM6 supports early cancer progression and metastasis by decreasing cell adhesion and promoting migration and invasion. Knockdown increases adhesion and reduces migration, proliferation, and colony formation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which signaling pathway is regulated by CEACAM6?",{"text":117,"@type":113},"CEACAM6 regulates ERK and AKT signaling and downstream target genes. Inhibiting AKT or ERK reduces CEACAM6-induced migration.",{"name":119,"@type":110,"acceptedAnswer":120},"How were CEACAM6 partners identified in the study?",{"text":121,"@type":113},"BirA-BioID followed by mass spectrometry identified Integrin Beta-1 (ITGB1) and PRKCD as direct molecular and functional partners of CEACAM6.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335438,1790466282,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nProteomic proﬁling reveals CEACAM6 function in driving gallbladder cancer aggressiveness through integrin receptor, PRKCD and AKT/ERK signaling  \nRaisatun Nisa Sugiyanto1, Carmen Metzger1, Aslihan Inal 1, Felicia Truckenmueller 1, Kira Gür1, Eva Eiteneuer 1, Thorben Huth 1, Angelika Fraas 1, Ivonne Heinze2, Joanna Kirkpatrick2, Carsten Sticht3, Thomas Albrecht 1,4, Benjamin Goeppert1,5,6, Tanja Poth7, Stefan Pusch 8,9, Arianeb Mehrabi4,10, Peter Schirmacher1,4, Junfang Ji 11, Alessandro Ori 2 and Stephanie Roessler 1,4 ✉  \n© The Author(s) 2024  \n\n|  | Gallbladder cancer (GBC) presents as an aggressive malignancy with poor patient outcome. Like other epithelial cancers, the mechanisms of GBC cancer progression remain vague and efforts in ﬁnding targeted therapies fall below expectations. This study combined proteomic analysis of formalin-ﬁxed parafﬁn-embedded (FFPE) GBC samples, functional and molecular characterization of potential oncogenes and identiﬁcation of potential therapeutic strategies for GBC. We identiﬁed Carcinoembryonic Antigenrelated Cell Adhesion Molecule 6 (CEACAM6) as one of the signiﬁcantly most upregulated proteins in GBC. CEACAM6 overexpression has been observed in other cancer entities but the molecular function remains unclear. Our functional analyses in vitro and in vivo mouse models revealed that CEACAM6 supported the initial steps of cancer progression and metastasis by decreasing cell adhesion and promoting migration and invasion of GBC cells. Conversely, CEACAM6 knockdown abolished GBC aggressiveness by increasing cell adhesion while reducing cell migration, cell proliferation, and colony formation. BirA-BioID followed by mass-spectrometry revealed Integrin Beta-1 (ITGB1) and Protein Kinase C Delta (PRKCD) as direct molecular and functional partners of CEACAM6 supporting GBC cell migration. ERK and AKT signaling and their downstream target genes were regulated by CEACAM6 and thus the treatment with AKT inhibitor capivasertib or ERK inhibitor ulixertinib mitigated the CEACAM6-induced migration. These ﬁndings demonstrate that CEACAM6 is crucially involved in gallbladder cancer progression by promoting migration and inhibiting cell adhesion through ERK and AKT signaling providing speciﬁc options for treatment of CEACAM6- |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| positive cancers. |  |  |\n|  | Cell Death and Disease (2024)15:780; [https://doi.org/10.1038/s41419-024-07171-x](https://doi.org/10.1038/s41419-024-07171-x) |  |\n|  |  |  |\n\nINTRODUCTION  \nGallbladder cancer (GBC) is the most common biliary tract cancer (BTC) and the sixth most common malignancy of the gastrointestinal tract [1] . Although GBC is classiﬁed as a rare cancer, there are distinct differences in GBC around the globe reaching epidemic levels in some regions and ethnicities [2] . The highest incidence rates are found in South America, northern India, and East Asia [3] . GBC 5-year survival rate is less than 20% due to diagnosis at progressed state and resistance to chemotherapy [2] . Less than 10% of patients with GBC are resectable [4] and more than 40% are diagnosed after cancer cells have spread to regional lymph nodes or the liver [5] . This late diagnosis and the resistance  \nof GBC to standard chemotherapy accounts for the poor prognosis of patients with GBC [3, 6] .  \nThe mechanisms of GBC metastasis and aggressiveness are largely unknown and understudied. The molecular signaling cascades involved in GBC progression are still unknown. Often patients with GBC are treated with the same therapy as other BTC diseases such as extrahepatic cholangiocarcinoma (eCCA), eventhough there is growing evidence of signiﬁcantly different molecular proﬁles of GBC and eCCA [7] . Thus, efforts in ﬁnding the potential targets and molecular drivers of GBC are ur","cbCaigovC7lYb04z","https://ap.wps.com/l/cbCaigovC7lYb04z","pdf",8868089,15,"English","# Introduction\n## Study aims and rationale\n## Background on GBC progression and treatment resistance\n# Results and findings (from abstract)\n## CEACAM6 upregulation and functional effects\n## Molecular partners and signaling mechanisms\n## Therapeutic inhibition of AKT/ERK","[{\"question\":\"What role does CEACAM6 play in gallbladder cancer aggressiveness?\",\"answer\":\"CEACAM6 supports early cancer progression and metastasis by decreasing cell adhesion and promoting migration and invasion. Knockdown increases adhesion and reduces migration, proliferation, and colony formation.\"},{\"question\":\"Which signaling pathway is regulated by CEACAM6?\",\"answer\":\"CEACAM6 regulates ERK and AKT signaling and downstream target genes. Inhibiting AKT or ERK reduces CEACAM6-induced migration.\"},{\"question\":\"How were CEACAM6 partners identified in the study?\",\"answer\":\"BirA-BioID followed by mass spectrometry identified Integrin Beta-1 (ITGB1) and PRKCD as direct molecular and functional partners of CEACAM6.\"}]","Proteomic Profiling Reveals CEACAM6 Function in Driving Gallbladder Cancer Aggressiveness through Integrin Receptor - PRKCD and AKT/ERK Signaling - positive cancers | PDF",1790010998,38]